Patent classifications
B01D15/32
METHODS OF PURIFYING CHARGE-SHIELDED FUSION PROTEINS
The present invention relates to method of purifying charge-shielded proteins from a cell lysate or periplasmic releasate using hydrophobic interaction chromatography as a first chromatography steps. Also provided herein are compositions comprising charge-shielded proteins and methods of treatment using purified charge-shielded proteins.
Protein complex by use of a specific site of an immunoglobulin fragment for linkage
Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
Phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof
The invention discloses a phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof. The phenylbenzofuran compound is represented by the formula ##STR00001##
The preparation method includes a traditional Chinese medicine extraction method by using Sophorae Tonkinensis Radix Et Rhizoma coarse powder as a raw material, and a chemical synthesis method. Active component of the composition is phenylbenzofuran compound, and composition is a drug, food or health product. The application of the phenylbenzofuran compound in the preparation of a drug, a food or health product for preventing or treating a tumor, wherein the tumor is nasopharyngeal carcinoma. The phenylbenzofuran compound is prepared by traditional Chinese medicine extraction method and chemical synthesis method. It has been proved that phenylbenzofuran has certain inhibition effect on nasopharyngeal carcinoma cells CNE-1 and CNE-2 by tumor cell experiments in vitro.
DIHYDROCHALCONES FROM BALANOPHORA HARLANDII
Methods of isolating dihydrochalcone compounds of Formula (I) from Balanophora harlandii are provided herein. Compositions and consumables comprising at least one sweetener and at least one dihydrochalcone compound described herein are also provided. Methods of enhancing the sweetness of a consumable, methods of making a consumable taste more like a sucrose-sweetened consumable and methods of preparing consumables are also detailed herein.
##STR00001##
PROCESS FOR PURIFYING C1-INH
The present invention relates to a process for purifying C1-esterase inhibitor (C1-INH), and more in particular a C1-INH concentrate.
METHOD FOR PRODUCING PURIFIED STEVIOL PRODUCT USING SIMULATED MOVING BED CHROMATOGRAPHY
Disclosed is a continuous process for the purification of steviol glycosides such as Rebaudioside D and/or Rebaudioside M extracted from the dried stevia leaves or extracted from a fermentation broth using continuous simulated moving bed processes and nanofiltration without the addition of organic solvents to obtain a purified steviol product comprising sweet steviol glycosides. The sweet steviol glycosides can be used as substitutes for caloric sweeteners in beverages and in other food items.
PURIFIED FISH PROTEASES WITH HIGH SPECIFIC ACTIVITIES AND ITS PROCESS OF PRODUCTION
The invention concerns a process for the preparation of fish proteases from fish viscera, preferably from cod (Gadus genus) viscera. The fish proteases produced according to the invention have high specific enzymatic activity and are useful for food uses, for biomedical applications, in histology and tissue culture.
Methods for quantitating individual antibodies from a mixture
The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
METHODS OF REDUCING THE ENZYMATIC HYDROLYSIS ACTIVITY RATE IN A COMPOSITION OBTAINED FROM A PURIFICATION PLATFORM
The present disclosure provides purification platforms comprising a depth filter step and/or a hydrophobic interaction chromatography (HIC) step. Also disclosed herein are methods of using the purification platforms described herein and compositions obtained therefrom, such as pharmaceutical compositions.
Systems and methods for two-dimensional chromatography
Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)—supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).